Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

Effective dose estimation for oncological and neurological PET/CT procedures

07-dic-2017 | Revista: EJNMMI Research

Martí-Climent JM (1,2), Prieto E (3,4), Morán V (3), Sancho L (3), Rodríguez-Fraile M (3,4), Arbizu J (3,4), García-Velloso MJ (3,4), Richter JA (3,4).

(1) Nuclear Medicine Department, Clínica Universidad de Navarra, 36, Pío XII Avenue, 31008, Pamplona, Spain.
(2) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
(3) Nuclear Medicine Department, Clínica Universidad de Navarra, 36, Pío XII Avenue, 31008, Pamplona, Spain.
(4) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.


BACKGROUND:
The aim of this study was to retrospectively evaluate the patient effective dose (ED) for different PET/CT procedures performed with a variety of PET radiopharmaceutical compounds. PET/CT studies of 210 patients were reviewed including Torso (n = 123),

Whole body (WB) (n = 36), Head and Neck Tumor (HNT) (n = 10), and Brain (n = 41) protocols with 18FDG (n = 170), 11C-CHOL (n = 10), 18FDOPA (n = 10), 11C-MET (n = 10), and 18F-florbetapir (n = 10). ED was calculated using conversion factors applied to the radiotracer activity and to the CT dose-length product.

RESULTS:
Total ED (mean ± SD) for Torso-11C-CHOL, Torso-18FDG, WB-18FDG, and HNT-18FDG protocols were 13.5 ± 2.2, 16.5 ± 4.5, 20.0 ± 5.6, and 15.4 ± 2.8 mSv, respectively, where CT represented 77, 62, 69, and 63% of the protocol ED, respectively. For 18FDG, 18FDOPA, 11C-MET, and 18F-florbetapir brain PET/CT studies, ED values (mean ± SD) were 6.4 ± 0.6, 4.6 ± 0.4, 5.2 ± 0.5, and 9.1 ± 0.4 mSv, respectively, and the corresponding CT contributions were 11, 14, 23, and 26%, respectively. In 18FDG PET/CT, variations in scan length and arm position produced significant differences in CT ED (p < 0.01). For dual-time-point imaging, the CT ED (mean ± SD) for the delayed scan was 3.8 ± 1.5 mSv.

CONCLUSIONS:
The mean ED for body and brain PET/CT protocols with different radiopharmaceuticals ranged between 4.6 and 20.0 mSv. The major contributor to total ED for body protocols is CT, whereas for brain studies, it is the PET radiopharmaceutical.

CITA DEL ARTÍCULO  EJNMMI Res. 2017 Dec;7(1):37. doi: 10.1186/s13550-017-0272-5. Epub 2017 Apr 24